Award type :
Product Development Award
Product Development Award
Product type :
Therapeutics
Therapeutics
Award year :
2018
2018
Project start date :
2019 / 06 / 24
2019 / 06 / 24
Project end date :
2020 / 10 / 06
2020 / 10 / 06
Project duration (months) :
15
15
Development stage :
Phase 2, 3
Phase 2, 3
Target disease :
Malaria
Malaria
Region served :
Low- and Middle-Income Countries
Low- and Middle-Income Countries
Recipient organization / Country of funding recipient organization :
MMV / Switzerland
MMV / Switzerland
Collaborator(s) / Country :
SK Biotek / Republic of Korea
SK Biotek / Republic of Korea
Funding amount(KRW) :
675,000,000
675,000,000
Single-Exposure Radical Cure (SERC) drugs are an ideal malarial treatment that can overcome the issue of parasite resistance and improve treatment compliance. The Medicines for Malaria Venture (MMV) has been pursuing the development of two potential single-dose treatments for malaria, OZ439 and MMV052, both of which require a key intermediate OZ2. This project aims to develop and scale a continuous manufacturing process for the intermediate OZ2. The feasibility of the continuous process manufacturing of OZ2 has been already established, and MMV aims to scale-up OZ2 in collaboration with SK Biotek’s continuous manufacturing process technology to meet desired production cost and manufacturing safety concerns.